title: Enhancement of wound healing by topical treatment with epidermal growth factor.
abstract: Experimental studies in animals have demonstrated that the topical application of epidermal growth factor accelerates the rate of epidermal regeneration of partial-thickness wounds and second-degree burns. We conducted a prospective, randomized, double-blind clinical trial using skin-graft-donor sites to determine whether epidermal growth factor would accelerate the rate of epidermal regeneration in humans. Paired donor sites were created in 12 patients who required skin grafting for either burns or reconstructive surgery. One donor site from each patient was treated topically with silver sulfadiazine cream, and one was treated with silver sulfadiazine cream containing epidermal growth factor (10 micrograms per milliliter). The donor sites were photographed daily, and healing was measured with the use of planimetric analysis. The donor sites treated with silver sulfadiazine containing epidermal growth factor had an accelerated rate of epidermal regeneration in all 12 patients as compared with that in the paired donor sites treated with silver sulfadiazine alone. Treatment with epidermal growth factor significantly decreased the average length of time to 25 percent and 50 percent healing by approximately one day and that to 75 percent and 100 percent healing by approximately 1.5 days (P less than 0.02). Histologic evaluation of punch-biopsy specimens taken from the centers of donor sites three days after the onset of healing supported these results. We conclude that epidermal growth factor accelerates the rate of healing of partial-thickness skin wounds. Further studies are required to determine the clinical importance of this finding.
authors.affiliation: Department of Surgery, Emory University, Atlanta.
authors.forename: G L
authors.initials: GL
authors.lastname: Brown
authors.forename: L B
authors.initials: LB
authors.lastname: Nanney
authors.forename: J
authors.initials: J
authors.lastname: Griffen
authors.forename: A B
authors.initials: AB
authors.lastname: Cramer
authors.forename: J M
authors.initials: JM
authors.lastname: Yancey
authors.forename: L J
authors.initials: LJ
authors.lastname: Curtsinger
authors.forename: L
authors.initials: L
authors.lastname: Holtzin
authors.forename: G S
authors.initials: GS
authors.lastname: Schultz
authors.forename: M J
authors.initials: MJ
authors.lastname: Jurkiewicz
authors.forename: J B
authors.initials: JB
authors.lastname: Lynch
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D002056:Burns / Q000601:surgery; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004815:Epidermal Growth Factor / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011897:Random Allocation; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000494:pharmacology; D016038:Skin Transplantation; D013268:Stimulation, Chemical; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D004815:Epidermal Growth Factor; D012837:Silver Sulfadiazine